S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
New Cash Law Will Be Disaster for Savers (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
New Cash Law Will Be Disaster for Savers (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Laser breakthrough could send stock soaring 2,467% (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
New Cash Law Will Be Disaster for Savers (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
New Cash Law Will Be Disaster for Savers (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Laser breakthrough could send stock soaring 2,467% (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
New Cash Law Will Be Disaster for Savers (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
New Cash Law Will Be Disaster for Savers (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Laser breakthrough could send stock soaring 2,467% (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
New Cash Law Will Be Disaster for Savers (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
New Cash Law Will Be Disaster for Savers (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Laser breakthrough could send stock soaring 2,467% (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
NASDAQ:RARE

Ultragenyx Pharmaceutical (RARE) Stock Forecast, Price & News

$36.43
-0.18 (-0.49%)
(As of 09/22/2023 ET)
Compare
Today's Range
$35.57
$36.74
50-Day Range
$34.92
$44.34
52-Week Range
$33.36
$54.98
Volume
682,699 shs
Average Volume
624,880 shs
Market Capitalization
$2.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$81.21

Ultragenyx Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
122.9% Upside
$81.21 Price Target
Short Interest
Bearish
5.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.28
Upright™ Environmental Score
News Sentiment
0.64mentions of Ultragenyx Pharmaceutical in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$379,400 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($8.65) to ($7.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

354th out of 966 stocks

Pharmaceutical Preparations Industry

147th out of 447 stocks


RARE stock logo

About Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

RARE Price History

RARE Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Ultragenyx Pharmaceutical (NASDAQ: RARE)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Q2 2023 Ultragenyx Pharmaceutical Inc Earnings Call
Ultragenyx Pharmaceutical Inc Q2 Loss misses estimates
This Biotech Stock Could Be a RARE Find
See More Headlines
Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

RARE Company Calendar

Last Earnings
8/03/2023
Today
9/22/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RARE
Employees
1,311
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$81.21
High Stock Price Forecast
$133.00
Low Stock Price Forecast
$47.00
Forecasted Upside/Downside
+122.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Net Income
$-707,420,000.00
Net Margins
-178.91%
Pretax Margin
-177.40%

Debt

Sales & Book Value

Annual Sales
$363.33 million
Book Value
$5.03 per share

Miscellaneous

Free Float
66,638,000
Market Cap
$2.60 billion
Optionable
Optionable
Beta
0.87

Social Links

10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Emil D. Kakkis M.D. (Age 63)
    Ph.D., Founder, Pres, CEO & Director
    Comp: $1.37M
  • Mr. John Richard Pinion IIMr. John Richard Pinion II (Age 57)
    Chief Quality Operations Officer & Exec. VP of Translational Sciences
    Comp: $806.19k
  • Mr. Erik HarrisMr. Erik Harris (Age 52)
    Exec. VP & Chief Commercial Officer
    Comp: $848.24k
  • Mr. Theodore A. HuizengaMr. Theodore A. Huizenga (Age 52)
    Sr. VP, Corp. Controller & Principal Accounting Officer
  • Mr. Dennis Karl HuangMr. Dennis Karl Huang (Age 58)
    Chief Technical Operations Officer & Gene Therapy Operations and Exec. VP
  • Ms. Danielle Keatley
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Karah Herdman Parschauer J.D.Ms. Karah Herdman Parschauer J.D. (Age 45)
    Chief Legal Officer & Exec. VP
  • Mr. Ernie W. Meyer (Age 59)
    Chief HR Officer & Exec. VP
  • Mr. Thomas R. Kassberg (Age 63)
    Chief Bus. Officer & Exec. VP
  • Mr. Vimal Srivastava (Age 58)
    Sr. VP of Bus. Devel. & Alliance Management













RARE Stock - Frequently Asked Questions

Should I buy or sell Ultragenyx Pharmaceutical stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RARE shares.
View RARE analyst ratings
or view top-rated stocks.

What is Ultragenyx Pharmaceutical's stock price forecast for 2023?

11 Wall Street research analysts have issued 1 year price objectives for Ultragenyx Pharmaceutical's stock. Their RARE share price forecasts range from $47.00 to $133.00. On average, they expect the company's share price to reach $81.21 in the next twelve months. This suggests a possible upside of 122.9% from the stock's current price.
View analysts price targets for RARE
or view top-rated stocks among Wall Street analysts.

How have RARE shares performed in 2023?

Ultragenyx Pharmaceutical's stock was trading at $46.33 at the beginning of 2023. Since then, RARE shares have decreased by 21.4% and is now trading at $36.43.
View the best growth stocks for 2023 here
.

When is Ultragenyx Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our RARE earnings forecast
.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($2.25) EPS for the quarter, missing the consensus estimate of ($2.11) by $0.14. The biopharmaceutical company earned $108.30 million during the quarter, compared to analysts' expectations of $107.10 million. Ultragenyx Pharmaceutical had a negative net margin of 178.91% and a negative trailing twelve-month return on equity of 220.54%. The company's revenue was up 21.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($2.26) earnings per share.

What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings?

Ultragenyx Pharmaceutical updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $425.00 million-$450.00 million, compared to the consensus revenue estimate of $437.55 million.

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.09%), Clearbridge Investments LLC (3.87%), Sands Capital Management LLC (3.74%), State Street Corp (3.45%), Alliancebernstein L.P. (2.12%) and Rock Springs Capital Management LP (1.94%). Insiders that own company stock include Camille L Bedrosian, Camille L Bedrosian, Corazon (Corsee) D Sanders, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, S Robson Walton, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
View institutional ownership trends
.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $36.43.

How much money does Ultragenyx Pharmaceutical make?

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $2.60 billion and generates $363.33 million in revenue each year. The biopharmaceutical company earns $-707,420,000.00 in net income (profit) each year or ($10.24) on an earnings per share basis.

How many employees does Ultragenyx Pharmaceutical have?

The company employs 1,311 workers across the globe.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for the company is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at ir@ultragenyx.com, or via fax at 415-483-8810.

This page (NASDAQ:RARE) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -